Merck, Ablynx partner to develop Nanobody candidates
As a part of the agreement, Ablynx will be responsible for the discovery of Nanobody candidates while Merck will be responsible for the research, development, manufacturing and commercialisation
Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.